Latest Surrozen News & Updates

See the latest news and media coverage for Surrozen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Surrozen

Biotechnology company developing Wnt-based ophthalmic therapies

surrozen.com

Headquarters: South San Francisco, United States
Company type: Private company
Number of employees: 50–67
Industry: Pharmaceuticals

Last updated October 20

Latest news about Surrozen

In short: Surrozen raised $95.1 million and secured FDA clearance to begin the DUET trial for SZN-8141.

Company announcements

October 20 Surrozen

Surrozen closes second tranche raising $95.1 million to fund pipeline through 2029

Funding extends cash runway into 2029, supporting SZN-8141's DUET study initiation and SZN-8143 clinical development following FDA IND clearance.

October 2 Surrozen

Surrozen receives FDA clearance for SZN-8141 IND

This milestone triggers the second closing of a private placement expected to raise $95.1 million. First patient dosing in the DUET study is planned for late 2026.

August 6 Surrozen

Surrozen reports Q2 2026 financial results and business update

The company plans IND submission for SZN-8141, DUET trial initiation, and highlighted a Boehringer Ingelheim milestone and PTAB patent win.

May 6 Surrozen

Surrozen reports Q1 2026 financial results

Cash at $106.9M. On track for SZN-8141 IND submission H2 2026. Net loss $127.5M.

Media coverage

October 20 The Globe and Mail

Surrozen Raises $95 Million, Extends Cash Runway

On October 20, 2026, Surrozen closed the second and final tranche of its March 2025 private placement, raising approximately $95.1 million in gross proceeds through...

October 12 AInvest

Surrozen (SRZN) Plunges 18%: The Silent Squeeze Behind the SZN-8141 Catalyst

- Surrozen SRZN-17.46% (SRZN) shares plummeted 18% amid profit-taking after the SZN-8141 IND submission catalyst, closing at $24.36. - Extreme volatility saw intraday swings from...

October 5 经济观察网

Surrozen, Inc. (SRZN) cumulative rise of approximately 103% over two days catalyzed by IND milestone and financing news

Economic Observer Network Surrozen, Inc. (SRZN) has recently seen a significant surge in its stock price driven by news regarding an Investigational New Drug (IND) milestone and financing. Recent Stock Performance From September 24 to 25, the stock price accumulated a gain of approximately 103% over two days. On September 24 alone, it surged by +108.42%, with trading volume expanding to approximately 11.53 million shares, as the market reacted strongly to the "IND milestone + financing release." The above content is compiled based on public information and does not constitute investment advice...

October 2 BioSpace

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

The FDA clearance of the SZN-8141 IND satisfies the second closing milestone under Surrozen's March 2025 two-tranche private ...

Never miss news about Surrozen

Track Surrozen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Surrozen competitors & trending companies

Browse news for competitors to Surrozen and other trending companies.